HBM Healthcare Investments AG Stock

Equities

HBMN

CH0012627250

Investment Management & Fund Operators

Real-time Estimate Cboe Europe 10:14:01 2024-06-10 am EDT 5-day change 1st Jan Change
207.8 CHF -0.36% Intraday chart for HBM Healthcare Investments AG +1.46% +14.46%
Sales 2025 * 76.9M 85.78M Sales 2026 * 132M 148M Capitalization 1.43B 1.6B
Net income 2025 * 51M 56.89M Net income 2026 * 107M 119M EV / Sales 2025 * 17.1 x
Net cash position 2025 * 117M 131M Net cash position 2026 * 126M 141M EV / Sales 2026 * 9.87 x
P/E ratio 2025 *
28.8 x
P/E ratio 2026 *
13.6 x
Employees 700
Yield 2025 *
3.45%
Yield 2026 *
3.8%
Free-Float 82.11%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.96%
1 week+0.24%
Current month-0.72%
1 month+4.29%
3 months+9.96%
6 months+23.65%
Current year+13.09%
More quotes
1 week
201.50
Extreme 201.5
211.50
1 month
195.40
Extreme 195.4
211.50
Current year
155.00
Extreme 155
211.50
1 year
135.20
Extreme 135.2
211.50
3 years
135.20
Extreme 135.2
367.00
5 years
135.20
Extreme 135.2
367.00
10 years
78.65
Extreme 78.65
367.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 01-06-30
Director of Finance/CFO 54 11-10-31
Corporate Secretary 60 -
Members of the board TitleAgeSince
Chairman 68 09-05-31
Director/Board Member 69 21-06-17
Director/Board Member 52 11-12-31
More insiders
Date Price Change Volume
24-06-10 209 +0.24% 2 195
24-06-07 208.5 +2.96% 4,652
24-06-06 202.5 -2.64% 6,254
24-06-05 208 +1.22% 3,223
24-06-04 205.5 -0.24% 10,652

Delayed Quote Swiss Exchange, June 10, 2024 at 08:12 am EDT

More quotes
HBM Healthcare Investments AG is a Switzerland-based venture capital company investing in emerging companies, mainly from the biotechnology and human medicine, diagnostics, as well as medical technology sectors. The Company focuses on unlisted companies, with two-thirds of assets being invested in private companies that offer high value-creation potential. As a holding company, it is involved in the acquisition, disposal and management of a diversified portfolio, as well as in financing and supporting the portfolio firms as a key partner. It focuses on companies with products either at an advanced stage of development or already available on the market. The primary investment areas are Western Europe and the United States. The Company's portfolio includes approximately 25 companies. As of March 31, 2012, the Company had six wholly owned subsidiaries, including three subsidiaries on Cayman Islands, two Barbados-based subsidiaries and a subsidiary in the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
208.5 CHF
Average target price
236 CHF
Spread / Average Target
+13.19%
Consensus

Annual profits - Rate of surprise